Award
National Institute on Aging 5R44AG091827-02
AD04 disease-modifying drug for Alzheimer's - preclinical and IND-enabling studies
Recipient
Not specified
Award Amount
$1,249,368.00
Ceiling
$1,249,368.00
Awarded
June 03, 2026
Identifier
5R44AG091827-02
NIH/NIA awarded a grant for preclinical and IND-enabling studies of AD04, a disease-modifying drug for Alzheimer's, with a focus on a cost-effective therapy requiring six injections per year.
Description
The project involves performing IND-enabling studies on a small molecule for Alzheimer's disease. The project aims to develop a cost-effective, disease-modifying therapy that requires only six subcutaneous injections per year. The project is part of the SBIR program, aiming to bring a novel therapy to market.